FibroGen Historical Balance Sheet

FGEN Stock

USD 0.40 0.06 12.33%

Trend analysis of FibroGen balance sheet accounts such as Other Current Liabilities of 200.7 M or Total Current Liabilities of 128.8 M provides information on FibroGen's total assets, liabilities, and equity, which is the actual value of FibroGen to its prevalent stockholders. By breaking down trends over time using FibroGen balance sheet statements, investors will see what precisely the company owns and what it owes to creditors or other parties at the end of each accounting year.

Cash Flow Balance Sheet Income Statement

Yuan Drop

Covid

Financial Statement Analysis is much more than just reviewing and examining FibroGen latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether FibroGen is a good buy for the upcoming year.

FibroGen Inventory

50.19 Million

Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in FibroGen. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in income.

To learn how to invest in FibroGen Stock, please use our How to Invest in FibroGen guide.

About FibroGen Balance Sheet Analysis

Balance Sheet is a snapshot of the financial position of FibroGen at a specified time, usually calculated after every quarter, six months, or one year. FibroGen Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of FibroGen and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which FibroGen currently owns. An asset can also be divided into two categories, current and non-current.

FibroGen Balance Sheet Chart

At this time, FibroGen's Non Currrent Assets Other are very stable compared to the past year. As of the 27th of February 2025, Cash And Short Term Investments is likely to grow to about 404.9 M, while Short and Long Term Debt Total is likely to drop about 89.2 M.

Total Assets Short Long Term Debt Total Total Current Liabilities Net Tangible Assets

Add Fundamental

Total Assets

Total assets refers to the total amount of FibroGen assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in FibroGen books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. The total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets.

Total Current Liabilities

Total Current Liabilities is an item on FibroGen balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of FibroGen are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. The total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations.

Net Tangible Assets

The total assets of a company minus any intangible assets such as patents, copyrights, and goodwill; it represents the physical assets of a company.

Most accounts from FibroGen's balance sheet are interrelated and interconnected. However, analyzing balance sheet accounts one by one will only give a small insight into FibroGen current financial condition. On the other hand, looking into the entire matrix of balance sheet accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in FibroGen. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in income.

To learn how to invest in FibroGen Stock, please use our How to Invest in FibroGen guide.At this time, FibroGen's Non Currrent Assets Other are very stable compared to the past year. As of the 27th of February 2025, Cash And Short Term Investments is likely to grow to about 404.9 M, while Short and Long Term Debt Total is likely to drop about 89.2 M.

	2022	2023	2024	2025 (projected)
Short and Long Term Debt Total	89.9M	170.5M	153.4M	89.2M
Total Assets	610.1M	423.5M	487.1M	665.2M

Short Long Term Debt Total Total Assets

FibroGen balance sheet Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Other Liab	Property Plant And Equipment Net	Current Deferred Revenue	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Other Assets	Long Term Debt	Cash And Short Term Investments	Net Receivables	Common Stock Total Equity	Common Stock Shares Outstanding	Short Term Investments	Non Current Liabilities Total	Other Current Assets	Other Stockholder Equity	Total Liab	Property Plant And Equipment Gross
Total Assets		-0.1	0.29	0.37	0.63	0.54	-0.3	0.31	-0.6	-0.34	0.4	0.62	-0.19	0.24	0.33	-0.71	0.96	0.48	0.75	0.54	0.63	0.4	0.39	0.66	0.4	-0.16
Short Long Term Debt Total	-0.1		-0.12	0.09	-0.21	0.23	0.23	0.46	0.11	-0.16	-0.12	-0.03	0.01	-0.03	-0.55	-0.25	-0.08	0.0	0.21	0.15	-0.08	0.4	-0.31	0.19	0.26	0.45
Other Current Liab	0.29	-0.12		0.9	-0.49	0.81	-0.71	0.55	0.1	-0.94	0.85	0.04	-0.51	-0.55	-0.17	-0.06	0.29	0.5	0.66	0.73	0.38	0.79	0.16	0.75	0.86	0.51
Total Current Liabilities	0.37	0.09	0.9		-0.34	0.95	-0.65	0.69	-0.07	-0.92	0.94	0.16	-0.46	-0.48	-0.07	-0.11	0.38	0.49	0.81	0.83	0.36	0.92	0.1	0.88	0.98	0.34
Total Stockholder Equity	0.63	-0.21	-0.49	-0.34		-0.17	0.24	-0.26	-0.62	0.47	-0.24	0.47	0.2	0.64	0.56	-0.47	0.6	0.05	0.1	-0.11	0.3	-0.33	0.3	-0.03	-0.34	-0.72
Other Liab	0.54	0.23	0.81	0.95	-0.17		-0.67	0.69	-0.18	-0.9	0.83	0.27	-0.52	-0.37	-0.08	-0.32	0.55	0.61	0.93	0.9	0.47	0.97	0.21	0.97	0.98	0.37
Property Plant And Equipment Net	-0.3	0.23	-0.71	-0.65	0.24	-0.67		-0.1	0.19	0.73	-0.61	-0.28	0.77	0.51	-0.23	0.12	-0.36	-0.55	-0.59	-0.72	-0.17	-0.56	-0.42	-0.69	-0.62	-0.35
Current Deferred Revenue	0.31	0.46	0.55	0.69	-0.26	0.69	-0.1		0.05	-0.63	0.63	0.05	0.0	-0.37	-0.25	-0.24	0.26	0.49	0.67	0.52	0.32	0.79	-0.35	0.61	0.76	0.41
Net Debt	-0.6	0.11	0.1	-0.07	-0.62	-0.18	0.19	0.05		-0.04	-0.22	-0.96	0.27	-0.11	-0.77	0.27	-0.71	-0.01	-0.34	-0.16	0.16	0.0	0.02	-0.27	-0.04	0.42
Retained Earnings	-0.34	-0.16	-0.94	-0.92	0.47	-0.9	0.73	-0.63	-0.04		-0.81	-0.12	0.56	0.56	0.24	0.19	-0.36	-0.55	-0.76	-0.84	-0.37	-0.9	-0.14	-0.86	-0.93	-0.61
Accounts Payable	0.4	-0.12	0.85	0.94	-0.24	0.83	-0.61	0.63	-0.22	-0.81		0.27	-0.39	-0.51	0.18	-0.04	0.42	0.44	0.73	0.76	0.28	0.77	-0.02	0.79	0.87	0.14
Cash	0.62	-0.03	0.04	0.16	0.47	0.27	-0.28	0.05	-0.96	-0.12	0.27		-0.36	-0.02	0.64	-0.31	0.74	0.06	0.42	0.24	-0.17	0.12	-0.07	0.35	0.14	-0.17
Non Current Assets Total	-0.19	0.01	-0.51	-0.46	0.2	-0.52	0.77	0.0	0.27	0.56	-0.39	-0.36		0.52	-0.15	0.1	-0.38	-0.45	-0.38	-0.61	-0.11	-0.45	-0.17	-0.56	-0.46	-0.32
Non Currrent Assets Other	0.24	-0.03	-0.55	-0.48	0.64	-0.37	0.51	-0.37	-0.11	0.56	-0.51	-0.02	0.52		0.0	-0.37	0.12	-0.46	-0.16	-0.39	0.19	-0.44	0.49	-0.32	-0.47	-0.56
Other Assets	0.33	-0.55	-0.17	-0.07	0.56	-0.08	-0.23	-0.25	-0.77	0.24	0.18	0.64	-0.15	0.0		0.03	0.41	0.08	0.06	-0.02	-0.2	-0.28	-0.01	0.01	-0.18	-0.65
Long Term Debt	-0.71	-0.25	-0.06	-0.11	-0.47	-0.32	0.12	-0.24	0.27	0.19	-0.04	-0.31	0.1	-0.37	0.03		-0.65	-0.38	-0.52	-0.43	-0.57	-0.27	-0.41	-0.47	-0.2	-0.04
Cash And Short Term Investments	0.96	-0.08	0.29	0.38	0.6	0.55	-0.36	0.26	-0.71	-0.36	0.42	0.74	-0.38	0.12	0.41	-0.65		0.48	0.73	0.57	0.54	0.4	0.29	0.68	0.4	-0.16
Net Receivables	0.48	0.0	0.5	0.49	0.05	0.61	-0.55	0.49	-0.01	-0.55	0.44	0.06	-0.45	-0.46	0.08	-0.38	0.48		0.62	0.67	0.62	0.6	0.14	0.67	0.56	0.31
Common Stock Total Equity	0.75	0.21	0.66	0.81	0.1	0.93	-0.59	0.67	-0.34	-0.76	0.73	0.42	-0.38	-0.16	0.06	-0.52	0.73	0.62		0.81	0.54	0.87	0.28	0.94	0.86	0.23
Common Stock Shares Outstanding	0.54	0.15	0.73	0.83	-0.11	0.9	-0.72	0.52	-0.16	-0.84	0.76	0.24	-0.61	-0.39	-0.02	-0.43	0.57	0.67	0.81		0.54	0.85	0.28	0.96	0.86	0.32
Short Term Investments	0.63	-0.08	0.38	0.36	0.3	0.47	-0.17	0.32	0.16	-0.37	0.28	-0.17	-0.11	0.19	-0.2	-0.57	0.54	0.62	0.54	0.54		0.44	0.51	0.55	0.41	-0.01
Non Current Liabilities Total	0.4	0.4	0.79	0.92	-0.33	0.97	-0.56	0.79	0.0	-0.9	0.77	0.12	-0.45	-0.44	-0.28	-0.27	0.4	0.6	0.87	0.85	0.44		0.07	0.91	0.98	0.53
Other Current Assets	0.39	-0.31	0.16	0.1	0.3	0.21	-0.42	-0.35	0.02	-0.14	-0.02	-0.07	-0.17	0.49	-0.01	-0.41	0.29	0.14	0.28	0.28	0.51	0.07		0.28	0.09	-0.14
Other Stockholder Equity	0.66	0.19	0.75	0.88	-0.03	0.97	-0.69	0.61	-0.27	-0.86	0.79	0.35	-0.56	-0.32	0.01	-0.47	0.68	0.67	0.94	0.96	0.55	0.91	0.28		0.91	0.3
Total Liab	0.4	0.26	0.86	0.98	-0.34	0.98	-0.62	0.76	-0.04	-0.93	0.87	0.14	-0.46	-0.47	-0.18	-0.2	0.4	0.56	0.86	0.86	0.41	0.98	0.09	0.91		0.45
Property Plant And Equipment Gross	-0.16	0.45	0.51	0.34	-0.72	0.37	-0.35	0.41	0.42	-0.61	0.14	-0.17	-0.32	-0.56	-0.65	-0.04	-0.16	0.31	0.23	0.32	-0.01	0.53	-0.14	0.3	0.45

Click cells to compare fundamentals

FibroGen Account Relationship Matchups

FibroGen balance sheet Accounts

	2020	2021	2022	2023	2024	2025 (projected)
Total Assets	826.8M	773.8M	610.1M	423.5M	487.1M	665.2M
Short Long Term Debt Total	37.7M	99.7M	89.9M	170.5M	153.4M	89.2M
Other Current Liab	118.9M	149.0M	224.8M	166.2M	191.2M	200.7M
Total Current Liabilities	163.2M	225.5M	273.6M	217.7M	250.3M	128.8M
Total Stockholder Equity	422.2M	209.1M	(21.4M)	(204.2M)	(183.7M)	(174.6M)
Other Liab	162.8M	178.1M	212.8M	241.4M	277.6M	147.1M
Property Plant And Equipment Net	63.3M	120.2M	100.5M	81.4M	73.2M	89.5M
Current Deferred Revenue	6.5M	15.9M	13.1M	12.7M	14.7M	10.0M
Net Debt	(640.7M)	(71.5M)	(65.8M)	56.8M	51.1M	53.6M
Retained Earnings	(974.0M)	(1.3B)	(1.6B)	(1.8B)	(1.7B)	(1.6B)
Accounts Payable	24.8M	26.1M	30.8M	18.0M	20.7M	13.0M
Cash	678.4M	171.2M	155.7M	113.7M	130.7M	239.8M
Non Current Assets Total	71.7M	299.8M	117.3M	92.0M	82.8M	146.7M
Non Currrent Assets Other	5.5M	8.0M	7.4M	5.3M	4.8M	6.5M
Other Assets	38.1M	8.0M	6.9M	1.0	1.15	1.09
Cash And Short Term Investments	686.5M	405.2M	422.0M	235.6M	270.9M	404.9M
Net Receivables	41.9M	25.4M	16.3M	41.1M	47.2M	26.7M
Common Stock Total Equity	854K	877K	914K	929K	1.1M	716.1K
Common Stock Shares Outstanding	89.9M	92.3M	93.6M	97.3M	111.9M	78.2M
Short Term Investments	8.1M	234.0M	266.3M	121.9M	140.2M	165.1M
Liabilities And Stockholders Equity	826.8M	773.8M	610.1M	423.5M	487.1M	665.2M
Non Current Liabilities Total	222.2M	319.2M	338.0M	368.1M	423.3M	261.8M
Other Current Assets	10.2M	12.5M	14.1M	13.4M	15.4M	19.5M
Other Stockholder Equity	1.4B	1.5B	1.5B	1.6B	1.9B	1.0B
Total Liab	385.4M	544.7M	611.6M	585.7M	673.6M	390.6M
Property Plant And Equipment Gross	63.3M	120.2M	100.5M	253.1M	291.0M	305.6M
Total Current Assets	755.1M	474.1M	492.8M	331.6M	381.3M	463.5M
Accumulated Other Comprehensive Income	(4.5M)	(4.2M)	(5.7M)	(6.9M)	(6.2M)	(5.9M)
Short Term Debt	13.5M	21.9M	10.3M	14.1M	16.2M	20.2M
Common Stock	914K	929K	942K	988K	1.1M	773.7K
Property Plant Equipment	42.7M	33.6M	120.2M	100.9M	90.8M	86.7M
Net Tangible Assets	516.1M	422.2M	209.1M	(21.4M)	(19.3M)	(18.3M)
Long Term Investments	244K	171.6M	9.4M	5.3M	4.8M	4.5M
Retained Earnings Total Equity	(715.8M)	(784.7M)	(974.0M)	(1.3B)	(1.1B)	(1.2B)
Capital Surpluse	1.2B	1.3B	1.4B	1.5B	1.7B	1.2B
Inventory	16.5M	31.0M	40.4M	41.6M	47.8M	50.2M

Pair Trading with FibroGen

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if FibroGen position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in FibroGen will appreciate offsetting losses from the drop in the long position's value.

Moving together with FibroGen Stock

0.65

CUE

Cue Biopharma

Pair Corr

Moving against FibroGen Stock

0.64	KURA	Kura Oncology	Pair Corr
0.63	ABOS	Acumen Pharmaceuticals	Pair Corr
0.47	INZY	Inozyme Pharma	Pair Corr
0.44	ILMN	Illumina Downward Rally	Pair Corr

The ability to find closely correlated positions to FibroGen could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace FibroGen when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back FibroGen - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling FibroGen to buy it.

The correlation of FibroGen is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as FibroGen moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if FibroGen moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.

Correlation analysis and pair trading evaluation for FibroGen can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.

Pair Correlation Correlation Matching

When determining whether FibroGen offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of FibroGen's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Fibrogen Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Fibrogen Stock:

How To Invest In FibroGen

Details

Is FibroGen Stock a good investment?

Details

What is FibroGen's Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

To learn how to invest in FibroGen Stock, please use our How to Invest in FibroGen guide.

You can also try the Equity Search module to search for actively traded equities including funds and ETFs from over 30 global markets.

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of FibroGen. If investors know FibroGen will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about FibroGen listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Quarterly Earnings Growth

0.536

Earnings Share

(1.15)

Revenue Per Share

1.81

Quarterly Revenue Growth

0.154

Return On Assets

(0.21)

The market value of FibroGen is measured differently than its book value, which is the value of FibroGen that is recorded on the company's balance sheet. Investors also form their own opinion of FibroGen's value that differs from its market value or its book value, called intrinsic value, which is FibroGen's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because FibroGen's market value can be influenced by many factors that don't directly affect FibroGen's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between FibroGen's value and its price as these two are different measures arrived at by different means. Investors typically determine if FibroGen is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, FibroGen's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

FibroGen Historical Balance Sheet

FibroGen Inventory

50.19 Million

About FibroGen Balance Sheet Analysis

FibroGen Balance Sheet Chart

Total Assets

Total Current Liabilities

Net Tangible Assets

FibroGen balance sheet Correlations

FibroGen Account Relationship Matchups

High Positive Relationship

High Negative Relationship

FibroGen balance sheet Accounts

Pair Trading with FibroGen

Moving together with FibroGen Stock

Moving against FibroGen Stock

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Liab	+ 0.98	Total Current Liabilities
Total Liab	+ 0.98	Other Liab
Total Liab	+ 0.98	Non Current Liabilities Total
Non Current Liabilities Total	+ 0.97	Other Liab
Other Stockholder Equity	+ 0.97	Other Liab
Cash And Short Term Investments	+ 0.96	Total Assets

Cash	- 0.96	Net Debt
Retained Earnings	- 0.94	Other Current Liab
Total Liab	- 0.93	Retained Earnings
Retained Earnings	- 0.92	Total Current Liabilities
Non Current Liabilities Total	- 0.9	Retained Earnings
Retained Earnings	- 0.9	Other Liab